Patents by Inventor Hwan-Mook Kim
Hwan-Mook Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11413261Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer matastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention as disclosed inhibit the growth of cancer cells and induce the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibit the expression of factors inducing resistance against radiation exposure, while having no side effects.Type: GrantFiled: November 22, 2019Date of Patent: August 16, 2022Assignee: METIMEDI PHARMACEUTICALS CO., LTDInventors: Hwan Mook Kim, Keun Yeong Jeong, Jae Jun Sim, Yeong Su Jang
-
Publication number: 20200255397Abstract: The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of autophagy-related diseases.Type: ApplicationFiled: March 27, 2020Publication date: August 13, 2020Applicant: AUTOPHAGYSCIENCES INC.Inventors: Hwan Mook KIM, Kwang Won JEONG, Seung Hyun OH, Sun Ki KIM, Jung Ju KIM, Seong-Won SONG
-
Patent number: 10662169Abstract: The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of autophagy-related diseases.Type: GrantFiled: August 19, 2016Date of Patent: May 26, 2020Assignee: AUTOPHAGYSCIENCES INC.Inventors: Hwan Mook Kim, Kwang Won Jeong, Seung Hyun Oh, Sun Ki Kim, Jung Ju Kim, Seong-Won Song
-
Publication number: 20200113855Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer matastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention as disclosed inhibit the growth of cancer cells and induce the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibit the expression of factors inducing resistance against radiation exposure, while having no side effects.Type: ApplicationFiled: November 22, 2019Publication date: April 16, 2020Applicant: METIMEDI PHARMACEUTICALS CO., LTDInventors: Hwan Mook KIM, Keun Yeong JEONG, Jae Jun SIM, Yeong Su JANG
-
Patent number: 10525022Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects.Type: GrantFiled: June 21, 2017Date of Patent: January 7, 2020Assignee: METIMEDI PHARMACEUTICALS CO., LTD.Inventors: Hwan Mook Kim, Keun Yeong Jeong, Jae Jun Sim, Yeong Su Jang
-
Publication number: 20180244644Abstract: The present invention relates to a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of autophagy-related diseases.Type: ApplicationFiled: August 19, 2016Publication date: August 30, 2018Applicant: AUTOPHAGYSCIENCES INC.Inventors: Hwan Mook KIM, Kwang Won JEONG, Seung Hyun OH, Sun Ki KIM, Jung Ju KIM, Seong-Won SONG
-
Publication number: 20170360727Abstract: The present invention relates to: a pharmaceutical composition for treating cancer containing, as an active ingredient, a metal lactate salt, which can be dissociated, in cancer cells, into lactate capable of effectively inhibiting actions such as proliferation, invasion, and metastasis of cancer cells by disturbing the metabolic processes of cancer cells; a pharmaceutical composition for inhibiting cancer metastasis; a food composition for alleviating cancer; and a method for treating cancer and a method for inhibiting cancer metastasis, both methods comprising a step of administering the lactate metal salt. The metal lactate salts of the present invention inhibits the growth of cancer cells and induces the death of cancer cells by disturbing the metabolic processes in the main energy production pathways of cancer, and inhibits the expression of factors inducing resistance against radiation exposure, while having no side effects.Type: ApplicationFiled: June 21, 2017Publication date: December 21, 2017Inventors: Hwan Mook KIM, Keun Yeong Jeong, Jae Jun Sim, Yeong Su Jang
-
Patent number: 9789114Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: GrantFiled: March 10, 2016Date of Patent: October 17, 2017Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Publication number: 20170239259Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: ApplicationFiled: December 12, 2014Publication date: August 24, 2017Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kyeong LEE, Mi Sun WON, Hwan Mook KIM, Song Kyu PARK, Kiho LEE, Ki Hoon LEE, Chang Woo LEE, Jung Joon LEE, Kyung Sook CHUNG, Bo Kyung KIM, Yinglan JIN, Seung-hee LEE
-
Publication number: 20160193215Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: ApplicationFiled: March 10, 2016Publication date: July 7, 2016Inventors: Kyeong LEE, Mi-Sun WON, Hwan-Mook KIM, Song-Kyu PARK, Ki-Ho LEE, Chang-Woo LEE, Bo-Kyung KIM, Hyun-Seung BAN, Kyung-Sook CHUNG, Naik RAVI
-
Patent number: 9315507Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: GrantFiled: September 27, 2012Date of Patent: April 19, 2016Assignees: Dongguk University Industry-Academic Cooperation Foundation, Korea Research Institute of Bioscience and BiotechnologyInventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Patent number: 8975241Abstract: There is provided a composition for preventing and treating obesity including high water-soluble ?-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble ?-cyclodextrin derivatives, especially, 2-hydroxypropyl-?-cyclodextrin (HP-?-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner.Type: GrantFiled: October 8, 2010Date of Patent: March 10, 2015Assignee: Song Ho Biomed Co., Ltd.Inventors: Gyoon-Hee Han, Yong Seok Choi, Sang-Bae Han, Jong-Ho Lee, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Jong-Soon Kang, Ki-Hoon Lee, Chang-Woo Lee
-
Patent number: 8940936Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: GrantFiled: October 17, 2011Date of Patent: January 27, 2015Assignees: Korea Research Institute of Bioscience and Biotechnology, Dongguk University Industry-Academic Cooperation FoundationInventors: Kyeong Lee, Mi Sun Won, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Ki Hoon Lee, Chang Woo Lee, Jung Joon Lee, Kyung Sook Chung, Bo Kyung Kim, Yinglan Jin, Seung-hee Lee
-
Publication number: 20140228357Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: ApplicationFiled: September 27, 2012Publication date: August 14, 2014Inventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Publication number: 20130237542Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: ApplicationFiled: October 17, 2011Publication date: September 12, 2013Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyeong Lee, Mi Sun Won, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Ki Hoon Lee, Chang Woo Lee, Jung Joon Lee, Kyung Sook Chung, Bo Kyung Kim, Yinglan Jin, Seung-hee Lee
-
Publication number: 20120196831Abstract: There is provided a composition for preventing and treating obesity including high water-soluble ?-cyclodextrin derivatives as an effective component. Specifically, the composition including the high water-soluble ?-cyclodextrin derivatives, especially, 2-hydroxypropyl-?-cyclodextrin (HP-?-CD, HPBCD) has effects on suppressing an increase in body weight induced by a high fat diet, suppressing appetite through decreasing an amount of dietary intake, decreasing body fat, decreasing liver weight, and significantly decreasing a sharp increase of blood sugar induced by intaking glucose and maltose on an empty stomach so that it can be useful for preventing and treating obesity, preventing and treating various diseases induced by obesity, and suppressing a sharp increase of blood sugar after dinner.Type: ApplicationFiled: October 8, 2010Publication date: August 2, 2012Applicant: SONG HO BIOMED CO., LTDInventors: Gyoon-Hee Han, Yong Seok Choi, Sang-Bae Han, Jong-Ho Lee, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Jong-Soon Kang, Ki-Hoon Lee, Chang-Woo Lee
-
Patent number: 8148541Abstract: Disclosed herein are rhodanine derivatives, a method for the preparation thereof, and a pharmaceutical composition containing the same. The rhodanine derivatives have inhibitory activity against protein phosphatases (PPase) such as PTP1B, Prl-3, LAR, CD45, Cdc25A, Cdc25B, Cdc25C, Yop, PP1 and VHR, and can be applied for the prevention and treatment of PPase-caused diseases, including autoimmune diseases, diabetes, impaired glucose intolerance, insulin resistance, obesity, cancers, etc. when the inhibitory activity thereof is modulated.Type: GrantFiled: December 8, 2006Date of Patent: April 3, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Seong Eon Ryu, Seung Jun Kim, Dae Gwin Jeong, Sang Hyeup Lee, Suk Kyeong Jung, Hwan Mook Kim, Song Kyu Park, Ki Ho Lee, Chang Woo Lee, Joong-Kwon Choi, Jin Hee Ahn
-
Patent number: 7846963Abstract: The present invention is related to new 2-oxo-cyclic compound the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.Type: GrantFiled: May 17, 2004Date of Patent: December 7, 2010Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Yung Hee Kho, Gyoon Hee Han, Ho Jae Lee, Bum Woo Park, Hyo Kon Chun, Hwan Mook Kim, Song Kyu Park, Sang Bae Han, Dong Kyu Ryu, Tae Gyu Chun, Jin Ha Lee, Chang Woo Lee, Ki Hoon Lee, Hee Yoon Lee
-
Publication number: 20100286207Abstract: The present invention is related to new 2-oxo-cyclic compound, the process for preparing them and a pharmaceutical composition comprising the same. The present invention provides a pharmaceutical composition for preventing and treating the inflammatory disease comprising the pain or inflammation caused by rheumatic disease, for example, rheumatoid arthritis, spondyloarthopathies, gout, osteoarthritis, systemic lupus erythematosus and juvenile arthritis, and inflammatory syndrome for example, from myositis, gingivitis, synovitis, ankylosing spondylitis, burstitis, burns and scar, inflammatory Crohn's disease, Types I diabetes. therefore, it can be used as the therapeutics for treating and preventing inflammatory diseases.Type: ApplicationFiled: July 20, 2010Publication date: November 11, 2010Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Yung Hee KHO, Gyoon Hee HAN, Ho Jae LEE, Bum Woo PARK, Hyo Kon CHUN, Hwan Mook KIM, Song Kyu PARK, Sang Bae HAN, Dong Kyu RYU, Tae Gyu CHUN, Jin Ha LEE, Chang Woo LEE, Ki Hoon LEE, Hee Yoon LEE
-
Publication number: 20100144708Abstract: The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.Type: ApplicationFiled: August 10, 2007Publication date: June 10, 2010Applicants: Korea Research Instititute of Bioscience and Biotechnology, Seoul Pharma, Co., Ltd.Inventors: Gyoon Hee Han, Eun Hyun Choi, Jee Sun Yang, Sung Hee Hong, Myung Sook Kim, Mi Sun Won, Kyung Sook Chung, Dong Myung Kim, Hyang Sook Yoo, Hwan Mook Kim, Song Kyu Park, Ki Ho Lee, Chang Woo Lee, Youn Woong Choi, Yong Mi Jeong, Byung Gu Min